痛风患者用非布索坦治疗的效果

What is the effect of treating gout patients with (febuxostat)? Febuxostat (Febuxostat) is a drug approved in 2009 for the treatment of chronic hyperuricemia. Compared with the traditional treatment drug allopurinol, febuxostat (febuxostat) is more effective in reducing uric acid. The most common adverse reactions are abnormal liver function, diarrhea and rash. Medication guidelines recommend a starting dose of 40 mg/d. In patients with mild to moderate renal impairment (creatinine clearance [CrCl] 30-89 mL/min), the starting dose is the same as in patients with normal renal function.

A multicenter, double-blind, randomized phase II clinical study evaluated the safety and efficacy of febuxostat (febuxostat) in gout. A total of 136 male and 17 female gout patients were randomized to receive placebo or this product (40, 80 or 120 mg/d). After 4 weeks, tests found that the serum uric acid concentration of patients in each dose group of febuxostat (febuxostat) was significantly lower than before treatment, with an average reduction of 37% in each group from low to high dose. %, 44% and 59%, while patients in the placebo group only decreased by 2%; the vast majority of patients persisted in completing the trial. The incidence of adverse reactions in the febuxostat (Febuxostat) and placebo groups was similar, and most of these adverse reactions were mild and self-limiting, with common ones including diarrhea, pain, back pain, headache and joint pain.

A phase III clinical trial compared the efficacy of febuxostat (80 and 120 mg/d) and allopurinol (300 mg/d) in parallel. A 1-year study of 760 patients showed that compared with the allopurinol group, more patients in the febuxostat (febuxostat) group achieved the main trial efficacy indicator - the sUA concentration was measured below 60mg/L in the last 3 months (all subjects were gout patients, and the pre-trial sUA concentrations were all above 80mg/L); after 52 weeks of treatment, febuxostat (febuxostat) failed to significantly reduce the area of tophi ( Tophi are aggregates of urate crystals unique to gout), but in the high-dose group in the early stages of the trial, this effect was more obvious; in each treatment group, patients with sUA concentrations reaching the target (<60 mg/L) were less likely to have gout attacks, and their tophi area had a more significant reduction; adverse reactions and their incidence rates were similar in each treatment group, including abnormal liver function, diarrhea, headache, joint-related signs and symptoms, and musculoskeletal/connective tissue symptoms.

From the above information, it seems that (Febuxostat) is very effective in treating gout patients.

Related hot article recommendations: